Market closedNon-fractional
Novavax/NVAX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Novavax
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
Ticker
NVAX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Gaithersburg, United States
Employees
1,543
Website
www.novavax.com
Novavax Metrics
BasicAdvanced
$2.3B
Market cap
-
P/E ratio
-$3.49
EPS
1.62
Beta
-
Dividend rate
Price and volume
Market cap
$2.3B
Beta
1.62
Financial strength
Current ratio
0.904
Quick ratio
0.624
Long term debt to equity
-66.287
Total debt to equity
-67.012
Interest coverage (TTM)
-26.61%
Management effectiveness
Return on assets (TTM)
-16.32%
Return on equity (TTM)
45.24%
Valuation
Price to revenue (TTM)
1.91
Price to book
-2.71
Price to tangible book (TTM)
-2.37
Price to free cash flow (TTM)
-3.701
Growth
Revenue change (TTM)
-26.66%
Earnings per share change (TTM)
-75.71%
3-year revenue growth (CAGR)
2.72%
3-year earnings per share growth (CAGR)
-28.39%
What the Analysts think about Novavax
Analyst Ratings
Majority rating from 6 analysts.
Novavax Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$94M
-67.80%
Net income
-$148M
-17.27%
Profit margin
-157.24%
156.93%
Novavax Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.58
-$1.26
-$1.44
-$1.05
-
Expected
-$1.39
-$1.83
-$0.45
-$1.06
$1.36
Surprise
-141.83%
-31.21%
221.19%
-1.32%
-
Novavax News
AllArticlesVideos
Novavax Ahead Of Q2 Earnings - Picking Apart The Sanofi Deal
Seeking Alpha·3 hours ago
Novavax Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
PRNewsWire·1 month ago
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Investors Business Daily·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novavax stock?
Novavax (NVAX) has a market cap of $2.3B as of July 26, 2024.
What is the P/E ratio for Novavax stock?
The price to earnings (P/E) ratio for Novavax (NVAX) stock is 0 as of July 26, 2024.
Does Novavax stock pay dividends?
No, Novavax (NVAX) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Novavax dividend payment date?
Novavax (NVAX) stock does not pay dividends to its shareholders.
What is the beta indicator for Novavax?
Novavax (NVAX) has a beta rating of 1.62. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Novavax stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.